AU2013224591A1 - Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer - Google Patents
Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer Download PDFInfo
- Publication number
- AU2013224591A1 AU2013224591A1 AU2013224591A AU2013224591A AU2013224591A1 AU 2013224591 A1 AU2013224591 A1 AU 2013224591A1 AU 2013224591 A AU2013224591 A AU 2013224591A AU 2013224591 A AU2013224591 A AU 2013224591A AU 2013224591 A1 AU2013224591 A1 AU 2013224591A1
- Authority
- AU
- Australia
- Prior art keywords
- inhibitor
- egfr
- clusterin
- seq
- carcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 66
- 229940121647 egfr inhibitor Drugs 0.000 title claims abstract description 59
- 229940086740 Clusterin inhibitor Drugs 0.000 title claims abstract description 42
- 201000011510 cancer Diseases 0.000 title claims abstract description 40
- 210000004027 cell Anatomy 0.000 claims description 132
- 230000007705 epithelial mesenchymal transition Effects 0.000 claims description 51
- 230000027455 binding Effects 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 36
- 239000012634 fragment Substances 0.000 claims description 32
- 239000000427 antigen Substances 0.000 claims description 31
- 108091007433 antigens Proteins 0.000 claims description 31
- 102000036639 antigens Human genes 0.000 claims description 31
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 30
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 30
- 201000009030 Carcinoma Diseases 0.000 claims description 16
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 16
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 16
- 229960001433 erlotinib Drugs 0.000 claims description 16
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 14
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 11
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 11
- 229960002584 gefitinib Drugs 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 229960005395 cetuximab Drugs 0.000 claims description 6
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 6
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 101000942697 Homo sapiens Clusterin Proteins 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 102000056179 human CLU Human genes 0.000 claims description 4
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 3
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 201000008275 breast carcinoma Diseases 0.000 claims description 3
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 3
- 229960002411 imatinib Drugs 0.000 claims description 3
- 229960004891 lapatinib Drugs 0.000 claims description 3
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 3
- 201000005296 lung carcinoma Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 229950010203 nimotuzumab Drugs 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 229960001972 panitumumab Drugs 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 3
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 2
- 201000003911 head and neck carcinoma Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical group 0.000 claims 5
- 208000010572 basal-like breast carcinoma Diseases 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 201000001514 prostate carcinoma Diseases 0.000 claims 1
- 102000001301 EGF receptor Human genes 0.000 abstract description 95
- 108060006698 EGF receptor Proteins 0.000 abstract description 95
- 230000014509 gene expression Effects 0.000 abstract description 44
- 230000001965 increasing effect Effects 0.000 abstract description 30
- 239000003112 inhibitor Substances 0.000 abstract description 22
- 102000000905 Cadherin Human genes 0.000 abstract description 19
- 108050007957 Cadherin Proteins 0.000 abstract description 19
- 102000003780 Clusterin Human genes 0.000 abstract description 18
- 108090000197 Clusterin Proteins 0.000 abstract description 18
- 230000026731 phosphorylation Effects 0.000 abstract description 15
- 238000006366 phosphorylation reaction Methods 0.000 abstract description 15
- 230000035945 sensitivity Effects 0.000 abstract description 8
- 230000004044 response Effects 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 17
- 230000035772 mutation Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 208000020816 lung neoplasm Diseases 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 201000005202 lung cancer Diseases 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 9
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 7
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 238000002512 chemotherapy Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000003213 activating effect Effects 0.000 description 6
- 230000002018 overexpression Effects 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000004899 motility Effects 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 102300050360 Clusterin isoform 1 Human genes 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 230000004544 DNA amplification Effects 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 101600114557 Homo sapiens Clusterin (isoform 1) Proteins 0.000 description 3
- 108091054455 MAP kinase family Proteins 0.000 description 3
- 102000043136 MAP kinase family Human genes 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000002771 cell marker Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 238000006471 dimerization reaction Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000009093 first-line therapy Methods 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 239000012130 whole-cell lysate Substances 0.000 description 3
- 101150039808 Egfr gene Proteins 0.000 description 2
- 101000614481 Homo sapiens Kidney-associated antigen 1 Proteins 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 102100040442 Kidney-associated antigen 1 Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010064390 Tumour invasion Diseases 0.000 description 2
- 108010065472 Vimentin Proteins 0.000 description 2
- 102000013127 Vimentin Human genes 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000009400 cancer invasion Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 208000037828 epithelial carcinoma Diseases 0.000 description 2
- 108700021358 erbB-1 Genes Proteins 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- -1 for example Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 2
- 102000016914 ras Proteins Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 210000005048 vimentin Anatomy 0.000 description 2
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102100030708 GTPase KRas Human genes 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
- 101001130298 Homo sapiens Ras-related protein Rab-25 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000785626 Homo sapiens Zinc finger E-box-binding homeobox 1 Proteins 0.000 description 1
- 101000723833 Homo sapiens Zinc finger E-box-binding homeobox 2 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
- 102100033011 Integrin beta-6 Human genes 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108050000637 N-cadherin Proteins 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 102100031528 Ras-related protein Rab-25 Human genes 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 102100026457 Zinc finger E-box-binding homeobox 1 Human genes 0.000 description 1
- 102100028458 Zinc finger E-box-binding homeobox 2 Human genes 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000025164 anoikis Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000008267 autocrine signaling Effects 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- BKRDNYHYNZJMPG-UHFFFAOYSA-A custirsen sodium Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].COCCOC1C(O)C(COP([O-])(=S)OC2C(C(OC2COP([O-])(=S)OC2C(C(OC2COP([O-])(=S)OC2C(C(OC2COP([O-])(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)OC2C(C(OC2COP([O-])(=S)OC2C(C(OC2COP([O-])(=S)OC2C(C(OC2COP([O-])(=S)OC2C(C(OC2CO)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C3=NC=NC(N)=C3N=C2)OCCOC)N2C3=C(C(NC(N)=N3)=O)N=C2)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(NC(=O)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C3=NC=NC(N)=C3N=C2)OCCOC)OC1N1C=C(C)C(=O)NC1=O BKRDNYHYNZJMPG-UHFFFAOYSA-A 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 108010021309 integrin beta6 Proteins 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 102000009929 raf Kinases Human genes 0.000 description 1
- 108010077182 raf Kinases Proteins 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- XLXOKMFKGASILN-UHFFFAOYSA-N rhodamine red-X Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(=O)(=O)NCCCCCC(O)=O)C=C1S([O-])(=O)=O XLXOKMFKGASILN-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261601786P | 2012-02-22 | 2012-02-22 | |
| US61/601,786 | 2012-02-22 | ||
| PCT/CA2013/000167 WO2013123588A1 (en) | 2012-02-22 | 2013-02-22 | Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2013224591A1 true AU2013224591A1 (en) | 2014-07-24 |
| AU2013224591A9 AU2013224591A9 (en) | 2015-07-23 |
Family
ID=49004878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013224591A Abandoned AU2013224591A1 (en) | 2012-02-22 | 2013-02-22 | Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9822170B2 (enExample) |
| EP (1) | EP2817028A4 (enExample) |
| JP (1) | JP2015512877A (enExample) |
| CN (1) | CN104159611A (enExample) |
| AU (1) | AU2013224591A1 (enExample) |
| BR (1) | BR112014020756A2 (enExample) |
| CA (1) | CA2862739A1 (enExample) |
| EA (1) | EA201491568A1 (enExample) |
| MX (1) | MX2014010164A (enExample) |
| NZ (1) | NZ626742A (enExample) |
| WO (1) | WO2013123588A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2776513C (en) | 2009-11-24 | 2017-08-01 | Alethia Biotherapeutics Inc. | Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume |
| MX2014010164A (es) | 2012-02-22 | 2014-11-25 | Alethia Biotherapeutics Inc | Co-uso de un inhibidor de clusterina con un inhibidor de egfr para tratar cancer. |
| RU2016135933A (ru) | 2014-02-07 | 2018-03-15 | Тон Вха Фарм. Ко., Лтд. | Композиция для противоракового вспомогательного лекарственного средства, содержащая средство, индуцирующее экспрессию rip3, в качестве активного ингредиента, способ скрининга противоракового вспомогательного лекарственного средства, повышающего чувствительность к противораковому лекарственному средству путем стимуляции экспрессии rip3, и способ контроля чувствительности к противораковому лекарственному средству |
| WO2016098041A1 (en) | 2014-12-18 | 2016-06-23 | Saarum Sciences Private Ltd | Establishment and use of an in vitro platform for emt |
| CN105987997B (zh) * | 2015-01-30 | 2017-12-29 | 江苏众红生物工程创药研究院有限公司 | 人组织激肽释放酶1荧光定量检测试纸卡 |
| CN105988004B (zh) * | 2015-01-30 | 2017-12-29 | 江苏众红生物工程创药研究院有限公司 | 人组织激肽释放酶1胶体金定量检测试纸卡 |
| CN109912716B (zh) * | 2017-12-13 | 2022-08-23 | 凯惠科技发展(上海)有限公司 | 一种egfr抗体及其制备方法和应用 |
| CN113474012B (zh) * | 2019-01-25 | 2023-09-08 | 湖南远泰生物技术有限公司 | Epcam抗体和epcam-car-t细胞 |
| CN114249832B (zh) * | 2020-09-24 | 2023-11-10 | 博源润生医药（杭州）有限公司 | 一种靶向cpsg4的人源化嵌合抗原受体及表达该嵌合抗原受体的免疫效应细胞及其应用 |
| MX2023012766A (es) * | 2021-04-27 | 2024-02-23 | Alethia Biotherapeutics Inc | Metodo para permitir la infiltracion de las celulas inmunitarias en los tumores. |
| CN117903305B (zh) * | 2023-12-05 | 2024-08-27 | 南京欧凯生物科技有限公司 | 针对雌二醇的单克隆抗体、基于其的检测试剂及其应用 |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3933850A1 (de) | 1989-10-06 | 1991-04-18 | Schering Ag | Zytolyse-inhibitor (zli), eine diese blutplasmaprotein kodierende dna-sequenz, sowie ein plasmid, ein wirtsorganismus und ein verfahren zur gewinnung dieses proteins |
| ATE204299T1 (de) | 1993-03-05 | 2001-09-15 | Bayer Ag | Humane monoklonale anti-tnf alpha antikörper |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6383808B1 (en) | 2000-09-11 | 2002-05-07 | Isis Pharmaceuticals, Inc. | Antisense inhibition of clusterin expression |
| US6818749B1 (en) | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
| WO2000034469A1 (en) | 1998-12-11 | 2000-06-15 | The Research Foundation Of State University Of New York At Albany | Compositions and methods for altering cell migration |
| EP1163254B1 (en) | 1999-02-26 | 2008-01-30 | The University of British Columbia | Trpm-2 antisense therapy |
| US6900187B2 (en) | 1999-02-26 | 2005-05-31 | The University Of British Columbia | TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications |
| WO2000064946A2 (en) | 1999-04-28 | 2000-11-02 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| US7291714B1 (en) | 1999-06-30 | 2007-11-06 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
| US20050208558A1 (en) | 1999-10-19 | 2005-09-22 | Applera Corporation | Detection kits, such as nucleic acid arrays, for detecting the expression or 10,000 or more Drosophila genes and uses thereof |
| US7569551B2 (en) | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| AU2001245280A1 (en) | 2000-03-07 | 2001-09-17 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| US7279294B2 (en) | 2000-04-03 | 2007-10-09 | The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services, Nih | Tumor markers in ovarian cancer |
| US6812339B1 (en) | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| WO2002072830A2 (en) | 2001-02-09 | 2002-09-19 | Incyte Genomics, Inc. | Proteins associated with cell growth, differentiation, and death |
| WO2003004646A2 (en) | 2001-04-04 | 2003-01-16 | Elan Corporation, Plc | Genetic analysis of peyers's patches and m cells and methods and compositions targeting peyer's patches and m cell receptors |
| US6881557B2 (en) | 2001-07-12 | 2005-04-19 | Arrowsmith Technologies Llp | Super humanized antibodies |
| US20030134301A1 (en) | 2001-07-27 | 2003-07-17 | Brooksbank Robert Alan | Identification and use of molecules implicated in pain |
| EP1478772A2 (en) | 2001-08-14 | 2004-11-24 | The General Hospital Corporation | Nucleic acid and amino acid sequences involved in pain |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US20070082337A1 (en) | 2004-01-27 | 2007-04-12 | Compugen Ltd. | Methods of identifying putative gene products by interspecies sequence comparison and biomolecular sequences uncovered thereby |
| WO2003054152A2 (en) | 2001-12-10 | 2003-07-03 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
| DE60322509D1 (de) | 2002-01-17 | 2008-09-11 | Univ British Columbia | Bispezifische antisense oligonukleotide die igfbp-2 und igfbp-5 inhibieren und deren verwendung |
| US20060088532A1 (en) | 2002-03-07 | 2006-04-27 | Kari Alitalo | Lymphatic and blood endothelial cell genes |
| KR100708398B1 (ko) | 2002-03-22 | 2007-04-18 | (주) 에이프로젠 | 인간화 항체 및 이의 제조방법 |
| WO2004005934A2 (en) | 2002-07-04 | 2004-01-15 | Oxford Glycosciences (Uk) Ltd | Toxicity markers |
| WO2004018676A2 (en) | 2002-08-21 | 2004-03-04 | The University Of British Columbia | Rnai probes targeting cancer-related proteins |
| KR101052289B1 (ko) | 2002-08-21 | 2011-07-27 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 클러스테린 양의 감소에 의한 흑색종의 치료 |
| EP2500438A3 (en) | 2002-09-25 | 2012-11-28 | Genentech, Inc. | Novel compositions and methods for the treatment of psoriasis |
| US20050048490A1 (en) | 2002-09-26 | 2005-03-03 | Incyte Corp. | Proteins associated with cell growth, differentiation, and death |
| JP2006516089A (ja) | 2002-10-02 | 2006-06-22 | ジェネンテック・インコーポレーテッド | 腫瘍の診断と治療のための組成物と方法 |
| US8722872B2 (en) | 2002-10-02 | 2014-05-13 | The University Of British Columbia | Compositions and methods for treatment of prostate and other cancers |
| DE10256900A1 (de) | 2002-11-29 | 2004-06-24 | Nemod Immuntherapie Ag | Tumorspezifische Erkennungsmoleküle |
| CA2514187A1 (en) | 2003-01-24 | 2004-08-12 | Bayer Pharmaceuticals Corporation | Expression profiles for colon cancer and methods of use |
| WO2005049806A2 (en) | 2003-03-14 | 2005-06-02 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
| CA2519681A1 (en) | 2003-03-28 | 2004-10-07 | Applied Research Systems Ars Holding N.V. | Use of clusterin for the treatment and/or prevention of peripheral neurological diseases |
| US20050255114A1 (en) | 2003-04-07 | 2005-11-17 | Nuvelo, Inc. | Methods and diagnosis for the treatment of preeclampsia |
| WO2004092379A2 (en) | 2003-04-18 | 2004-10-28 | The University Of British Columbia | Method for treatment of angiogenic disorders |
| WO2004092378A2 (en) | 2003-04-18 | 2004-10-28 | The University Of British Columbia | Method for treatment of cancerous angiogenic disorders |
| CA2527321A1 (en) * | 2003-05-30 | 2004-12-23 | Genomic Health, Inc. | Gene expression markers for response to egfr inhibitor drugs |
| WO2005014849A2 (en) | 2003-07-03 | 2005-02-17 | Euro-Celtique, S.A. | Genes associated with responses to neuropathic pain |
| CA2533803A1 (en) | 2003-07-29 | 2005-02-10 | Bristol-Myers Squibb Company | Biomarkers of cyclin-dependent kinase modulation |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US7288250B2 (en) | 2003-09-11 | 2007-10-30 | Critical Therapeutics, Inc. | Monoclonal antibodies against HMGB1 |
| AT412785B (de) | 2003-12-04 | 2005-07-25 | Kungl Andreas J Dr | Gag-bindungsproteine |
| WO2005060457A2 (en) | 2003-12-04 | 2005-07-07 | Pdl Biopharma, Inc. | Treatment of inflammatory bowel diseases with anti-ip-10 antibodies |
| GB0329254D0 (en) | 2003-12-17 | 2004-01-21 | Univ Manchester | Treatment of viral infections |
| GB0329958D0 (en) | 2003-12-24 | 2004-01-28 | Univ Manchester | Treatment of viral infections |
| US7309487B2 (en) | 2004-02-09 | 2007-12-18 | George Inana | Methods and compositions for detecting and treating retinal diseases |
| RU2390353C2 (ru) * | 2004-02-12 | 2010-05-27 | Мерк Патент Гмбх | Высококонцентрированные жидкие композиции анти-egfr антител |
| ITRM20040098A1 (it) | 2004-02-25 | 2004-05-25 | Univ Roma | Anticorpi oligoclonali anticlasterina per la diagnosi di neoplasie e la predizione del loro grado di malignita', metodo diagnostico e kit relativi. |
| WO2005094899A1 (en) | 2004-04-02 | 2005-10-13 | The University Of British Columbia | Clusterin antisense therapy for treatment of cancer |
| KR20070049637A (ko) | 2004-07-09 | 2007-05-11 | 트리패스 이미징, 인코포레이티드 | 난소 질환 검출 방법 및 조성물 |
| GB0421639D0 (en) | 2004-09-29 | 2004-10-27 | Proteome Sciences Plc | Methods and compositions relating to alzheimer's disease |
| JP2008520186A (ja) | 2004-10-01 | 2008-06-19 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | 哺乳類ｅａｇ１イオンチャネルタンパク質に対する新規の抗体 |
| WO2006056054A1 (en) | 2004-11-23 | 2006-06-01 | The University Of British Columbia | Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels |
| US7883858B2 (en) | 2005-01-27 | 2011-02-08 | Institute For Systems Biology | Methods for identifying and monitoring drug side effects |
| ATE454455T1 (de) | 2005-01-27 | 2010-01-15 | Five Prime Therapeutics Inc | Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung |
| WO2006089586A1 (en) | 2005-02-23 | 2006-08-31 | Medizinische Universität Graz | Use of a compound with clusterin activity for the treatment of diseases associated with the deposition of abnormal proteins |
| JP2008531060A (ja) | 2005-03-04 | 2008-08-14 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 相補性決定残基の合理的改変を介して免疫グロブリン可変領域をヒト化する方法 |
| US20080307537A1 (en) | 2005-03-31 | 2008-12-11 | Dana-Farber Cancer Institute, Inc. | Compositions and Methods for the Identification, Assessment, Prevention, and Therapy of Neurological Diseases, Disorders and Conditions |
| EP1869224A4 (en) | 2005-04-15 | 2009-11-18 | Oncomethylome Sciences Inc | METHYLATION MARKERS FOR THE DIAGNOSIS AND TREATMENT OF CANCERS |
| US7972770B2 (en) | 2005-08-16 | 2011-07-05 | Memorial Sloan-Kettering Cancer Center | Methods of detection of cancer using peptide profiles |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| AU2006291990B2 (en) * | 2005-09-13 | 2012-05-31 | National Research Council Of Canada | Methods and compositions for modulating tumor cell activity |
| ES2611608T3 (es) | 2005-10-21 | 2017-05-09 | Catalyst Biosciences, Inc. | Proteasas modificadas que inhiben la activación del complemento |
| US7972802B2 (en) | 2005-10-31 | 2011-07-05 | University Of Washington | Lipoprotein-associated markers for cardiovascular disease |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| EP1963534A2 (en) | 2005-12-19 | 2008-09-03 | Genizon Biosciences Inc. | Genemap of the human gene associated with crohn's disease |
| EP1963551A4 (en) | 2005-12-21 | 2009-07-29 | Univ Montreal | MARKINGS FOR MEMORY T CELLS AND USES THEREOF |
| KR100679173B1 (ko) | 2006-02-28 | 2007-02-06 | 주식회사 바이오인프라 | 위암 진단용 단백질 마커 및 이를 이용한 진단키트 |
| PL2004688T5 (pl) | 2006-03-23 | 2014-09-30 | Bioarctic Neuroscience Ab | Ulepszone przeciwciała wobec protofibryli oraz ich zastosowania |
| WO2007123976A2 (en) | 2006-04-18 | 2007-11-01 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody profiling for determination of patient responsiveness |
| AU2007284651B2 (en) | 2006-08-09 | 2014-03-20 | Institute For Systems Biology | Organ-specific proteins and methods of their use |
| WO2008049239A1 (en) | 2006-10-27 | 2008-05-02 | Mount Sinai Hospital | Endometrial biomarkers |
| WO2008085024A1 (en) | 2007-01-12 | 2008-07-17 | Erasmus University Medical Center Rotterdam | Identification and detection of peptides relating to specific disorders |
| GB0703652D0 (en) | 2007-02-26 | 2007-04-04 | Univ Bradford | Method for the allosteric modulation of beta1 integrin |
| US8568993B2 (en) | 2007-07-02 | 2013-10-29 | Purdue Research Foundation | Detection of glycopeptides and glycoproteins for medical diagnostics |
| WO2009034562A2 (en) | 2007-09-11 | 2009-03-19 | Dublin City University | A method of assessing lung squamous cell carcinoma status in an individual |
| US8617877B2 (en) | 2007-11-02 | 2013-12-31 | The Johns Hopkins University | Cardiac stem cell and myocyte secreted paracrine factors |
| US7923253B2 (en) | 2007-11-05 | 2011-04-12 | Battelle Memorial Institute | Method for identifying type I diabetes mellitus in humans |
| EP2071336A1 (en) * | 2007-12-13 | 2009-06-17 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Serum proteomic for finding diagnostic markers and for monitoring therapeutical intervention in treatment of hepatocellular carcinoma |
| WO2009117030A2 (en) | 2007-12-19 | 2009-09-24 | Macrogenics, Inc. | Improved compositions for the prevention and treatment of smallpox |
| EP2080812A1 (en) | 2008-01-18 | 2009-07-22 | Transmedi SA | Compositions and methods of detecting post-stop peptides |
| EP2240196A2 (en) | 2008-01-22 | 2010-10-20 | Compugen Ltd. | Clusterin derived peptide |
| WO2009116860A1 (en) | 2008-03-17 | 2009-09-24 | Vereniging Het Nederlands Kanker Instituut | Markers providing prognosis of metastasis among cancer patients |
| KR101110758B1 (ko) | 2008-06-02 | 2012-02-15 | 경북대학교 산학협력단 | 뇌졸중 표적용 펩티드 및 이의 용도 |
| US8148088B2 (en) | 2008-07-18 | 2012-04-03 | Abgent | Regulation of autophagy pathway phosphorylation and uses thereof |
| WO2010030980A2 (en) * | 2008-09-12 | 2010-03-18 | University Of South Florida | Akt and clusterin as biomarkers of chemotherapeutic responsiveness |
| JP5861242B2 (ja) | 2009-04-17 | 2016-02-16 | ナショナル リサーチ カウンシル オブ カナダ | クラステリンのペプチドリガンド及びその使用 |
| CA2776513C (en) | 2009-11-24 | 2017-08-01 | Alethia Biotherapeutics Inc. | Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume |
| MX2014010164A (es) | 2012-02-22 | 2014-11-25 | Alethia Biotherapeutics Inc | Co-uso de un inhibidor de clusterina con un inhibidor de egfr para tratar cancer. |
-
2013
- 2013-02-22 MX MX2014010164A patent/MX2014010164A/es unknown
- 2013-02-22 BR BR112014020756A patent/BR112014020756A2/pt not_active IP Right Cessation
- 2013-02-22 JP JP2014557950A patent/JP2015512877A/ja active Pending
- 2013-02-22 AU AU2013224591A patent/AU2013224591A1/en not_active Abandoned
- 2013-02-22 WO PCT/CA2013/000167 patent/WO2013123588A1/en not_active Ceased
- 2013-02-22 EA EA201491568A patent/EA201491568A1/ru unknown
- 2013-02-22 CN CN201380010493.0A patent/CN104159611A/zh active Pending
- 2013-02-22 US US14/374,967 patent/US9822170B2/en active Active
- 2013-02-22 NZ NZ626742A patent/NZ626742A/en not_active IP Right Cessation
- 2013-02-22 EP EP13751181.2A patent/EP2817028A4/en not_active Withdrawn
- 2013-02-22 CA CA2862739A patent/CA2862739A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2862739A1 (en) | 2013-08-29 |
| WO2013123588A9 (en) | 2014-09-04 |
| US20150044220A1 (en) | 2015-02-12 |
| EA201491568A1 (ru) | 2014-11-28 |
| US9822170B2 (en) | 2017-11-21 |
| WO2013123588A1 (en) | 2013-08-29 |
| JP2015512877A (ja) | 2015-04-30 |
| BR112014020756A2 (pt) | 2017-07-04 |
| EP2817028A1 (en) | 2014-12-31 |
| CN104159611A (zh) | 2014-11-19 |
| EP2817028A4 (en) | 2015-11-04 |
| NZ626742A (en) | 2016-06-24 |
| MX2014010164A (es) | 2014-11-25 |
| AU2013224591A9 (en) | 2015-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9822170B2 (en) | Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer | |
| EP3903828A1 (en) | Combination of antibody-drug conjugate and kinase inhibitor | |
| US20150231238A1 (en) | Overcoming resistance to erbb pathway inhibitors | |
| US20160303127A1 (en) | Combination therapy with c-met and egfr antagonists | |
| US20110262436A1 (en) | Treatment method | |
| WO2009106096A1 (en) | Treatment of resistant tumors with trifunctional antibodies | |
| US12220604B2 (en) | Treatment of metastatic brain tumor by administration of an antibody-drug conjugate | |
| WO2012018404A2 (en) | Use of her3 binding agents in prostate treatment | |
| KR20230043109A (ko) | 항체-약물 접합체 및 atr 억제제의 조합 | |
| WO2021260583A1 (en) | Combination of antibody-drug conjugate and dna-pk inhibitor | |
| US20220064306A1 (en) | Treatment of Non-Small Cell Lung Cancer with EGFR Mutations | |
| CN114340679A (zh) | 用于治疗对pd-1/pd-l1信号传导抑制剂无应答的癌症的方法和药物 | |
| US20230233540A1 (en) | Combination of antibody-drug conjugate and cdk9 inhibitor | |
| AU2008308761A1 (en) | NLRR-1 antagonists and uses thereof | |
| EA050561B1 (ru) | Лечение немелкоклеточного рака легкого с мутациями egfr | |
| HK40045208A (en) | Treatment of metastatic brain tumor by administration of antibody-drug conjugate | |
| HK40054690A (en) | Combination of antibody-drug conjugate and kinase inhibitor | |
| EA046932B1 (ru) | Лечение метастатической опухоли головного мозга путем введения конъюгата антитело-лекарственное средство | |
| HK40063551A (en) | Method and medicament for treating cancer unresponsive to pd-1/pd-l1 signaling inhibitor | |
| KR20250172902A (ko) | 항체-약물 콘주게이트 투여에 의한 전이성 뇌종양의 치료 | |
| AU2015213411A1 (en) | Combination therapy with c-met and EGFR antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SREP | Specification republished | ||
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |